Dear Reader,

We wish you a happy and prosperous New Year!

In 2013, we are looking forward to further improving the content and quality of *Human Vaccines and Immunotherapeutics* (*HV&I*). In addition to regular research paper submissions, the editorial team strives to provide a variety of solicited content including reviews, commentaries, company profiles and portraits of distinguished scientists in the field of vaccines and immunotherapeutics.

We regularly publish a Special Issue or Special Focus on timely topics related to vaccines and immunotherapeutics. Last year, we had a Special Issue on *Influenza Vaccines* (issue 8--1), and Special Focus sections on *Provenge* (8--4), *Cancer Vaccine Development* (8--8 and 8--9), and *Allergy Vaccines and Immunotherapeutics* (8--10). Additional Special Focus topics are planned for 2013.

*HV&I* also publishes Meeting Supplements where selected speakers are invited to contribute to a Special Issue or Section based on presentations at a conference. In 2012, we produced a Special Section on the Vaccine Renaissance Conference V (issue 8--7) as well as a Special Issue on the DNA Vaccines 2011 conference (8--11). Several Meeting Supplements are planned for 2013, including a Special Issue for the World Congress on Vaccines, Immunization and Immunotherapy (9--3).

In this first issue of the year, we draw your attention to four contributions related to the topic of ***New Targets***: nicotine vaccines (reviewed by Goniewicz, p), plant-derived VLP vaccines (reviewed by Chen, p), clinical trial data of a poxvirus-vectored candidate tuberculosis vaccine (Rowland, p), and preclinical development of a DNA vaccine against *Clostridium difficile* (Jin, p). Four papers in this issue deal with ***HPV***: a German study on HPV acceptance (Stöcker, p), a transgenic tobacco-expressed HPV vaccine candidate (Hongli, p), burden of HPV-related cancers in Appalachia US (Reiter, p), and HPV vaccine introduction in India (commentary by Verma, p). In the rubric ***Target Populations***, we feature three papers: explaining low immunization rates among nurses (Baron-Epel, p), adolescent vaccine trials in Africa (commentary by Abrams, p), and Iran's national immunization program (Moradi-Lakeh, p). Different aspects of ***Influenza*** are discussed: the seasonal influenza vaccine Intanza (reviewed by Leroux-Roels, p), antibody persistence after H1N1 2009 influenza vaccination (Tandale, p), post-marketing surveillance of pandemic H1N1 influenza vaccine Nasovac (Kulkarni, p), additive preventive effect of influenza and pneumococcal vaccines (Mahamat, p), safety and immunogenicity of 2010--1 trivalent influenza vaccine following previous vaccination with AS03-adjuvanted H1N1 influenza vaccine (Scheifele, p), and the effectiveness of adjuvanted seasonal influenza vaccines in preventing hospitalization in the elderly (Gasparini, p). One review on mini-chaperones as potential immuno-stimulators in vaccine design (Bolhassani, p) is published in the section ***Immunotherapy***. Seven contributions in this issue fall into the category ***Licensed Vaccines***: the changing epidemiology of meningococcal disease in North America (reviewed by Baccarini, p), effectiveness of universal mass vaccination against varicella (Tafuri, p), immunogenicity and safety of pentavalent rotavirus vaccine in Indian infants (Lokeshwar, p), safety of post-exposure rabies prophylaxis during pregnancy (Huang, p), environmental factors associated with a mumps outbreak in vaccinated orthodox Jewish boys (Parker Fiebelkorn, p), outbreaks of wild-type Poliovirus in previously polio-free countries (Arya, p), and horizontal transmission of live vaccines (Kulkarni, p).

Furthermore, this issue features a Special Focus on ***Cancer***. One research study looked at phenotype endothelial cell variations (heterogeneity) in the context of the development of an efficient tumor vaccine (Lokhov, p). Four commentaries discuss therapeutic vaccines as an ultimate personalized therapy (Gulley, p), the potential of nanotechnology for developing vesicle-based cancer immunotherapy (Tian, p), surrogate measures of activity for cancer-targeting vaccines (Nemunaitis, p), and peptide vaccines for hepatocellular carcinoma (Nobuoka, p).

As usual, our monthly News, Policy and Profiles (NP&P) section provides you with a selection of the latest news in the field of vaccines and immunotherapeutics. As part of our NP&P track we are pleased to present the German biotech company immatics biotechnologies GmbH. The company focuses on developing advanced therapeutic vaccines that are active against cancers with a high unmet medical need. Dr. Paul Higham, CEO of immatics, kindly agreed to answer our questions. Please contact the Acquisitions Editor Eva Riedmann ([eva\@landesbioscience.com]{.ul}), if you would like to see your company/organization portrayed in a future issue of *HV&I*. The NP&P track is also an excellent platform to share your opinion on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. Suggestions for commentaries and opinion pieces are welcome.

Last but not least, the current issue features our recognition of the Reviewer of the Year, Dr. John Schiller (page xy). We also thank all peer reviewers for their reviews, and reviewers during 2012, who also are listed in this issue.

We offer several popular website features: an [iPad application]{.ul} that allows you to read the full issue of *HV&I* anywhere, just as you would the print issue, an [RSS feed]{.ul} to see the latest published papers, and a *HV&I* [facebook]{.ul} account for daily updates.

Sincerely,

Ronald Ellis PhD

*Editor-in-Chief*

Eva M. Riedmann PhD

*Acquisitions Editor*

Previously published online: [www.landesbioscience.com/journals/vaccines/article/23606](http://www.landesbioscience.com/journals/vaccines/article/23606/)
